Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05893043 · ClinicalTrials.gov registry record · Phase 1
A Study of Multiple Ascending Doses of GSBR-1290 in Japanese and Non-Japanese Healthy Participants
A Phase 1 study, sponsored by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT05893043 is a Phase 1 study that has completed, run by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics. The registered enrollment target is 18 participants.
The verdict
NCT05893043, a Phase 1 study, has completed, sponsored by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of this study is to assess safety and tolerability of multiple oral doses of GSBR-1290 (capsule) in healthy adult Japanese participants compared to non-Japanese participants.
Interventions
- OTHER Placebo
- DRUG GSBR-1290
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2023-04-24 |
| Est. Completion | 2023-06-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05893043
The ClinicalTrials.gov registry entry for NCT05893043 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05893043 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05893043 about?
NCT05893043 is a clinical study titled "A Study of Multiple Ascending Doses of GSBR-1290 in Japanese and Non-Japanese Healthy Participants". The purpose of this study is to assess safety and tolerability of multiple oral doses of GSBR-1290 (capsule) in healthy adult Japanese participants compared to non-Japanese participants.
What is the current status of trial NCT05893043?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2023-04-24. Estimated completion is 2023-06-28.
What interventions are being tested in trial NCT05893043?
The interventions under investigation include: Placebo (OTHER), GSBR-1290 (DRUG).
Who is sponsoring clinical trial NCT05893043?
This trial is sponsored by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.